| Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 A Goldhirsch, JN Ingle, RD Gelber, AS Coates, B Thürlimann, HJ Senn Annals of oncology 20 (8), 1319-1329, 2009 | 1986 | 2009 |
| 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4) F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ... Annals of Oncology 29 (8), 1634-1657, 2018 | 1332 | 2018 |
| 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, MS Aapro, F André, ... Annals of Oncology 31 (12), 1623-1649, 2020 | 1245 | 2020 |
| ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆ A Gennari, F André, CH Barrios, J Cortes, E de Azambuja, A DeMichele, ... Annals of oncology 32 (12), 1475-1495, 2021 | 946 | 2021 |
| ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) F Cardoso, A Costa, L Norton, E Senkus, M Aapro, F Andre, CH Barrios, ... The Breast 23 (5), 489-502, 2014 | 872 | 2014 |
| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 545 | 2021 |
| Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study V Launay‐Vacher, S Oudard, N Janus, J Gligorov, X Pourrat, O Rixe, ... Cancer 110 (6), 1376-1384, 2007 | 477 | 2007 |
| 1st International consensus guidelines for advanced breast cancer (ABC 1) F Cardoso, A Costa, L Norton, D Cameron, T Cufer, L Fallowfield, ... The Breast 21 (3), 242-252, 2012 | 424 | 2012 |
| Preclinical pharmacology of the taxanes: implications of the differences J Gligorov, JP Lotz The oncologist 9 (S2), 3-8, 2004 | 357 | 2004 |
| First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity C Brignone, M Gutierrez, F Mefti, E Brain, R Jarcau, F Cvitkovic, ... Journal of translational medicine 8, 1-11, 2010 | 286 | 2010 |
| Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study X Pivot, J Gligorov, V Müller, P Barrett-Lee, S Verma, A Knoop, ... The lancet oncology 14 (10), 962-970, 2013 | 268 | 2013 |
| A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS–Cancer‐Associated thrombosis study GT Gerotziafas, A Taher, H Abdel‐Razeq, E AboElnazar, AC Spyropoulos, ... The Oncologist 22 (10), 1222-1231, 2017 | 266 | 2017 |
| Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in … S Gourgou-Bourgade, D Cameron, P Poortmans, B Asselain, D Azria, ... Annals of Oncology 26 (5), 873-879, 2015 | 237 | 2015 |
| Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of … X Pivot, J Gligorov, V Müller, G Curigliano, A Knoop, S Verma, V Jenkins, ... Annals of oncology 25 (10), 1979-1987, 2014 | 201 | 2014 |
| Adjuvant treatments for triple-negative breast cancers H Joensuu, J Gligorov Annals of oncology 23, vi40-vi45, 2012 | 180 | 2012 |
| Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study JY Pierga, T Petit, T Delozier, JM Ferrero, M Campone, J Gligorov, ... The lancet oncology 13 (4), 375-384, 2012 | 168 | 2012 |
| Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2–overexpressing stage II or III … BP Coudert, R Largillier, L Arnould, P Chollet, M Campone, D Coeffic, ... Journal of clinical oncology 25 (19), 2678-2684, 2007 | 168 | 2007 |
| Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line … G von Minckwitz, F Puglisi, J Cortes, E Vrdoljak, N Marschner, C Zielinski, ... The lancet oncology 15 (11), 1269-1278, 2014 | 167 | 2014 |
| Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer … J Gligorov, D Doval, J Bines, E Alba, P Cortes, JY Pierga, V Gupta, ... The Lancet Oncology 15 (12), 1351-1360, 2014 | 164 | 2014 |
| Fall in C-peptide during first 4 years from diagnosis of type 1 diabetes: variable relation to age, HbA1c, and insulin dose W Hao, S Gitelman, LA DiMeglio, D Boulware, CJ Greenbaum, ... Diabetes care 39 (10), 1664-1670, 2016 | 158 | 2016 |
ROUZIER RomanVerified email at curie.fr
